NCT05919264 2026-04-09FOG-001 in Locally Advanced or Metastatic Solid TumorsParabilis Medicines, Inc.Phase 1/2 Recruiting595 enrolled
NCT07334119 2026-02-19Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid TumorsMyeloid TherapeuticsPhase 1 Recruiting60 enrolled
NCT04278144 2025-09-15A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsBolt Biotherapeutics, Inc.Phase 1/2 Terminated175 enrolled
NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts
NCT04925284 2025-04-04Study of XB002 in Subjects With Solid Tumors (JEWEL-101)ExelixisPhase 1 Completed269 enrolled
NCT03667716 2025-01-17COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.Compugen LtdPhase 1 Completed121 enrolled
NCT04570839 2024-07-18COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.Compugen LtdPhase 1/2 Completed48 enrolled
NCT04042116 2022-12-20A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorClovis Oncology, Inc.Phase 1/2 Suspended227 enrolled
NCT03241173 2022-09-27A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed52 enrolled 25 charts